Efficacy of a Semi Automated Commercial Closed System for Autologous Leukocyte- and Platelet-Rich Plasma (l-prp) Production in Dogs: A Preliminary Study

Perego, Roberta; Spada, Eva; Baggiani, Luciana; Martino, Piera Anna; Proverbio, Daniela

doi:10.3390/ani10081342

Cited by 6 publications

(7 citation statements)

References 88 publications

(163 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This included much lower PDGF-BB concentrations but at the same time much higher TGF-β1 concentrations in canine concentrates and lysates as compared to the equine counterparts [ 29 ]. These species’ differences in growth factor concentrations and canine growth factor levels widely correspond to the literature, although the results described in different studies are diverse [ 52 , 53 , 54 , 55 ]. In addition, the cPL obtained after lysis showed a significantly lower PDGF-BB concentration in comparison to the canine concentrate.…”

Section: Discussionsupporting

confidence: 74%

Platelet Lysate for Mesenchymal Stromal Cell Culture in the Canine and Equine Species: Analogous but Not the Same

Hagen

Holland²,

Brandt³

et al. 2022

Animals

View full text Add to dashboard Cite

Platelet lysate (PL) is an attractive platelet-based therapeutic tool and has shown promise as xeno-free replacement for fetal bovine serum (FBS) in human and equine mesenchymal stromal cell (MSC) culture. Here, we established a scalable buffy-coat-based protocol for canine PL (cPL) production (n = 12). The cPL was tested in canine adipose MSC (n = 5) culture compared to FBS. For further comparison, equine adipose MSC (n = 5) were cultured with analogous equine PL (ePL) or FBS. During canine blood processing, platelet and transforming growth factor-β1 concentrations increased (p < 0.05 and p < 0.001), while white blood cell concentrations decreased (p < 0.05). However, while equine MSC showed good results when cultured with 10% ePL, canine MSC cultured with 2.5% or 10% cPL changed their morphology and showed decreased metabolic activity (p < 0.05). Apoptosis and necrosis in canine MSC were increased with 2.5% cPL (p < 0.05). Surprisingly, passage 5 canine MSC showed less genetic aberrations after culture with 10% cPL than with FBS. Our data reveal that using analogous canine and equine biologicals does not entail the same results. The buffy-coat-based cPL was not adequate for canine MSC culture, but may still be useful for therapeutic applications.

show abstract

Section: Discussionsupporting

confidence: 74%

Platelet Lysate for Mesenchymal Stromal Cell Culture in the Canine and Equine Species: Analogous but Not the Same

Hagen

Holland²,

Brandt³

et al. 2022

Animals

View full text Add to dashboard Cite

show abstract

“…This is similar to two of five systems in one study (12) and two of five in another (18). In a study carried out by Perego et al (24) evaluating the CPUNT 20 system, the final product did not have a significantly different leukocyte count compared with whole blood. This system; however, has two settings which gives the user the option of allowing or disallowing leukocytes in the final product.…”

Section: Discussionsupporting

confidence: 78%

“…Only 3 of the 10 subjects demonstrated a final plasma product with a higher concentration of platelets when compared to the initial CBC on peripheral blood (prior to processing). Unlike the system studied here, Perego et al (24) showed that the CPUNT 20 system consistently concentrates canine platelets. However, the Stryker RegenKit PRP system is not the only system of its kind that was shown not to concentrate platelets efficiently.…”

Section: Discussionmentioning

confidence: 67%

“…Only two of the five systems final products examined by Carr et al (12) had no significant change of monocyte concentration compared to whole blood (two had significantly decreased concentrations and one had an increased concentration) and all had significantly different concentrations of lymphocytes compared to whole blood (two had significantly decreased concentrations and three had an increased concentration). The CPUNT 20 system's final PRP product had an increased concentration of both monocytes and lymphocytes when compared to whole blood (24). This shows the vast variability of numbers and types of leukocytes present across the various final products produced by the different machines.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

The Stryker Regenkit PRP Kit Does Not Concentrate Canine Platelets

et al. 2020

View full text Add to dashboard Cite

Platelet Rich Plasma (PRP) works to recruit growth factors, anti-inflammatory mediators, and blood supply to an area that may not heal well under normal conditions (e.g., joints, tendons, ligaments). Previous research has demonstrated that various PRP systems create vastly different final products. The objective of this study was to evaluate the cellular composition of the final plasma product using the Stryker RegenKit system in dogs. A peripheral blood sample was obtained from ten healthy adult dogs and compared to the final plasma product. A standard CBC was performed prior to testing and an additional sample was processed according the manufacturing guidelines for obtaining PRP (10 ml total blood). Comparisons of mean platelet count, erythrocyte count, and leukocyte count were made between the peripheral blood sample and the final plasma product. Results showed that there was no significant difference in platelet count between the peripheral blood CBC and final PRP CBC (p = 0.349). There were significantly fewer erythrocytes and leukocytes in the final plasma product when compared with peripheral blood (p = <0.0001, p = 0.0318, respectively). These results indicate that the Stryker Regenkit PRP Kit decreases leukocyte and erythrocyte concentrations but does not consistently change platelet concentrations in its final plasma product. This study, in combination with results from similar studies, may allow clinicians to better choose the appropriate PRP system to treat various musculoskeletal conditions in dogs.

show abstract

“…At D0, L-PRP was prepared using a semi-automated closed system previously evaluated by the same authors in dogs [ 53 ]. Briefly, the system is composed of a single use, sterile collection kit for blood sampling (CpunT 20 mL, Eltek S.p.A, Hone, AO, Italy), a dedicated centrifuge (Eltek Group, Hone, AO, Italy) and an automatic instrument for the separation of the L-PRP (Eltek Group, Hone, AO, Italy).…”

Section: Methodsmentioning

confidence: 99%

Use of Autologous Leucocyte- and Platelet-Rich Plasma (L-PRP) in the Treatment of Aural Hematoma in Dogs

Perego

Spada

E³

et al. 2021

Veterinary Sciences

Self Cite

View full text Add to dashboard Cite

Leukocyte- and platelet-rich plasma (L-PRP) can accelerate the healing process by providing increased concentrations of platelet-derived growth factors. The objective of this study was to evaluate the clinical effect of L-PRP in the treatment of canine aural hematomas associated with otitis externa. Twenty mL of citrated whole blood was collected from each of the 17 dogs included and autologous L-PRP was produced. The aural hematoma was drained and 0.5–1 mL of L-PRP was injected. The dogs were examined weekly until 7 days after complete clinical healing. A final clinical follow-up was performed 6 weeks after the first treatment with L-PRP. If there was recurrence of the aural hematoma at the first follow-up, the treatment was repeated. In total, 2/17 cases were lost after the first follow-up. In 5/17 dogs, a short-term recurrence occurred. In 12/15 cases, complete clinical resolution was achieved with a single L-PRP application (Group A1) and in 3/15 with two treatments (Group A2). The mean time to complete clinical resolution was 16 ± 8.7 days (A1) and 23.3 ± 4 days (A2), respectively. No side effects were reported. The in situ administration of autologous L-PRP resulted in a complete resolution of the aural hematoma in all dogs that completed the clinical trial.

show abstract

Efficacy of a Semi Automated Commercial Closed System for Autologous Leukocyte- and Platelet-Rich Plasma (l-prp) Production in Dogs: A Preliminary Study

Cited by 6 publications

References 88 publications

Platelet Lysate for Mesenchymal Stromal Cell Culture in the Canine and Equine Species: Analogous but Not the Same

Platelet Lysate for Mesenchymal Stromal Cell Culture in the Canine and Equine Species: Analogous but Not the Same

The Stryker Regenkit PRP Kit Does Not Concentrate Canine Platelets

Use of Autologous Leucocyte- and Platelet-Rich Plasma (L-PRP) in the Treatment of Aural Hematoma in Dogs

Contact Info

Product

Resources

About